Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HILLARY E NORTON

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1093911323
CMS profile
366074
Location
SANTA FE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$451,727.73

709 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $124,073.44 116
AbbVie, Inc. $88,035.40 108
Lilly USA, LLC $83,300.99 170
UCB, Inc. $57,009.26 94
Amgen Inc. $40,235.31 65
Janssen Scientific Affairs, LLC $21,269.72 18
GENZYME CORPORATION $10,169.74 13
Celgene Corporation $9,842.52 27
Eli Lilly and Company $8,922.80 23
Regeneron Healthcare Solutions, Inc. $3,818.98 10
Janssen Biotech, Inc. $1,750.82 9
UCB Biosciences Inc. $1,575.00 1
Regeneron Pharmaceuticals, Inc. $841.32 9
SANOFI-AVENTIS U.S. LLC $295.58 11
Horizon Therapeutics plc $214.86 11
PFIZER INC. $154.18 13
Mallinckrodt Enterprises LLC $66.25 3
Radius Health, Inc. $56.79 3
Genentech USA, Inc. $54.01 3
GlaxoSmithKline, LLC. $23.19 1
Ferring Pharmaceuticals Inc. $17.57 1

Page 14 of 15; records 651–700 of 709 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HILLARY E NORTON

NPI 1093911323 · CMS profile ID 366074

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SANTA FE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 14 of 15; records 651–700 of 709 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093911323?year=2019&recipient=provider&page=14#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 14 of 15; records 651–700 of 709 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093911323?year=2019&recipient=provider&page=14#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 14 of 15; records 651–700 of 709 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093911323?year=2019&recipient=provider&page=14#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 14 of 15; records 651–700 of 709 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1093911323?year=2019&recipient=provider&page=14#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

709 matching records · $451,727.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 709 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 651–700 of 709.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $124.0402/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392569 CMS
Lilly USA, LLC $5,175.0002/19/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657845377 CMS
Novartis Pharmaceuticals Corporation $18.6702/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836867 CMS
Janssen Biotech, Inc. $7.9502/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658621213 CMS
Lilly USA, LLC $77.3202/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657862465 CMS
Amgen Inc. $1,500.0002/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392579 CMS
Amgen Inc. $4,000.0002/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392581 CMS
Lilly USA, LLC $48.6702/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657858935 CMS
Novartis Pharmaceuticals Corporation $41.8502/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836865 CMS
Novartis Pharmaceuticals Corporation $505.0002/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836991 CMS
Lilly USA, LLC $331.2002/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657852175 CMS
Lilly USA, LLC $253.4902/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657852177 CMS
Lilly USA, LLC $15.3602/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657855691 CMS
Lilly USA, LLC $31.5002/09/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865943 CMS
Amgen Inc. $148.5102/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392543 CMS
Amgen Inc. $40.4402/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392551 CMS
Eli Lilly and Company $55.2602/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657845403 CMS
Eli Lilly and Company $20.0002/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657852199 CMS
Amgen Inc. $125.0002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392539 CMS
Amgen Inc. $121.3102/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392547 CMS
Amgen Inc. $253.5702/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392555 CMS
Amgen Inc. $372.6102/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392557 CMS
Horizon Therapeutics plc $15.8602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691458185 CMS
Lilly USA, LLC $110.2402/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865939 CMS
PFIZER INC. $4.5502/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672395103 CMS
AbbVie, Inc. $407.0002/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647767093 CMS
Celgene Corporation $19.4102/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672727921 CMS
SANOFI-AVENTIS U.S. LLC $2.7402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694325585 CMS
UCB, Inc. $19.9802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688253473 CMS
AbbVie, Inc. $3,325.0001/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647767097 CMS
Novartis Pharmaceuticals Corporation $1,105.6301/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836885 CMS
Novartis Pharmaceuticals Corporation $3,030.0001/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836887 CMS
Novartis Pharmaceuticals Corporation $72.7001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836889 CMS
AbbVie, Inc. $57.3001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647767099 CMS
Novartis Pharmaceuticals Corporation $17.7401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659836989 CMS
AbbVie, Inc. $19.9001/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647766915 CMS
AbbVie, Inc. $593.9901/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647767091 CMS
AbbVie, Inc. $130.6701/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647767095 CMS
Celgene Corporation $82.5401/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672726407 CMS
Lilly USA, LLC $16.6601/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657855689 CMS
Lilly USA, LLC $2.4301/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865941 CMS
Mallinckrodt Enterprises LLC $23.4401/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704751023 CMS
Amgen Inc. $5.4201/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662392535 CMS
Celgene Corporation $56.3701/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672839631 CMS
Celgene Corporation $82.9001/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844837 CMS
Celgene Corporation $53.6801/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844843 CMS
Celgene Corporation $381.7801/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672859945 CMS
Celgene Corporation $56.6601/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672859981 CMS
Celgene Corporation $224.8801/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672872491 CMS
Celgene Corporation $4,518.0001/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673013011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $451,727.73 709
PY2020 $201,194.46 250
PY2021 $218,778.11 281
PY2022 $216,676.54 316
PY2023 $295,538.93 370
PY2024 $307,513.00 342
PY2025 $193,172.56 294

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $17,365.77 4
PY2025 Principal investigator $1,111,623.00 42
PY2024 Recipient $2,820.02 2
PY2024 Principal investigator $1,278,725.00 17
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $199,743.62 13
PY2022 Recipient $3,699.00 4
PY2022 Principal investigator $67,946.96 6
PY2021 Principal investigator $124,878.06 9
PY2020 Recipient $1,575.00 1
PY2020 Principal investigator $210,123.70 20
PY2019 Recipient $24,721.00 1
PY2019 Principal investigator $235,790.61 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $7,965.10 12/22/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,024.60 12/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289780
Principal investigator 1 ABBVIE INC. $8,583.80 12/04/2025 Non-covered Recipient Entity
HILLARY E NORTON MD PC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528392
Principal investigator 1 SANOFI US SERVICES INC. $133.97 12/02/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093548
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $46.20 12/01/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $268.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,135.60 11/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288649
Principal investigator 1 ABBVIE INC. $902.20 11/05/2025 Non-covered Recipient Entity
HILLARY E NORTON MD PC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521339
Principal investigator 1 SANOFI US SERVICES INC. $188.93 10/20/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093516
Principal investigator 1 SANOFI US SERVICES INC. $7,274.80 10/20/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093521
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,707.63 10/09/2025 Non-covered Recipient Entity
INSPIRE SANTA FE MEDICAL GROUP
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190305333
Principal investigator 1 ABBVIE INC. $5,349.00 10/08/2025 Non-covered Recipient Entity
HILLARY E NORTON MD PC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202513551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,150.00 10/08/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,440.00 10/08/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,790.00 10/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286325
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 10/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286327
Principal investigator 1 SANOFI US SERVICES INC. $4,070.21 09/15/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093493
Principal investigator 1 ABBVIE INC. $8,100.00 09/04/2025 Non-covered Recipient Entity
HILLARY E NORTON MD PC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202509100
Principal investigator 1 SANOFI US SERVICES INC. $5,604.30 09/03/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093499
Principal investigator 1 SANOFI US SERVICES INC. $135.00 08/18/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093469
Principal investigator 1 SANOFI US SERVICES INC. $410.00 08/18/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226093475
Principal investigator 1 SANOFI US SERVICES INC. $40.00 08/18/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226093482
Principal investigator 1 Amgen Inc. $893.86 07/28/2025 Non-covered Recipient Entity
INSPIRE SANTA FE MEDICAL GROUP
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246642744
Principal investigator 1 SANOFI US SERVICES INC. $4,937.40 07/28/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093462
Principal investigator 1 SANOFI US SERVICES INC. $200.53 07/21/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093456
Recipient SANOFI US SERVICES INC. $262.82 07/02/2025 Covered Recipient Physician Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226123803
Recipient SANOFI US SERVICES INC. $7,786.80 07/02/2025 Covered Recipient Physician A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226123807
Recipient SANOFI US SERVICES INC. $8,879.00 07/02/2025 Covered Recipient Physician Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226123810
Principal investigator 1 Eli Lilly and Company $163.55 05/08/2025 Non-covered Recipient Entity
DERMATOLOGY CENTE FOR SKIN HEALTH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879843
Principal investigator 1 Amgen Inc. $62,087.98 04/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246642950
Principal investigator 1 Amgen Inc. $24,031.72 04/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
P4 Uncontrolled Gout FORWARD II No dispute reported 06/30/2026 1246642958
Principal investigator 1 Amgen Inc. $184,457.76 04/15/2025 Non-covered Recipient Entity
INSPIRE SANTA FE MEDICAL GROUP
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246642752
Principal investigator 1 SANOFI US SERVICES INC. $17,755.70 04/14/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226093438
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 04/07/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093375
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 04/02/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226093369
Recipient Eli Lilly and Company $437.15 03/25/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187870985
Principal investigator 1 SANOFI US SERVICES INC. $13,575.00 02/18/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226093380
Principal investigator 1 Eli Lilly and Company $5,965.08 02/11/2025 Non-covered Recipient Entity
CAMC HEALTH EDUCATION AND RESEARCH INSTITUTE INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878251
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 02/04/2025 Non-covered Recipient Entity
HILLARY E NORTON MD
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190309052
Principal investigator 1 SANOFI US SERVICES INC. $1,749.39 01/21/2025 Non-covered Recipient Entity
Hillary E Norton Md Pc Inspire Santa Fe Medical Group
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226093393
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,000.00 01/17/2025 Non-covered Recipient Entity
HILLARY E NORTON MD
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190309054
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,758.99 01/15/2025 Non-covered Recipient Entity
INSPIRE SANTA FE MEDICAL GROUP
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190305331
Principal investigator 1 Amgen Inc. $640,558.80 01/14/2025 Non-covered Recipient Entity
INSPIRE SANTA FE MEDICAL GROUP
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246642748
Principal investigator 1 Eli Lilly and Company $22,747.00 01/13/2025 Non-covered Recipient Entity
INTERSPOND LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187882088
Principal investigator 1 Eli Lilly and Company $84.90 01/09/2025 Non-covered Recipient Entity
INTERSPOND LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187882440
Principal investigator 1 Eli Lilly and Company $13,236.00 01/06/2025 Non-covered Recipient Entity
HILLARY E. NORTON MD PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187882490